TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Provided By GlobeNewswire – Last update:

Quotes Stocks Mentioned

Article Mentions:

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively

Target guidance of approximately $875-900 million in total global revenue for 2026

Read more at globenewswire.com